Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arbutus Biopharma Corporation stock | $4.14

Learn how to easily invest in Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation is a biotechnology business based in the US. Arbutus Biopharma Corporation shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma Corporation employs 76 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arbutus Biopharma Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arbutus Biopharma Corporation stock price (NASDAQ: ABUS)

Use our graph to track the performance of ABUS stocks over time.

Arbutus Biopharma Corporation shares at a glance

Information last updated 2021-10-16.
Latest market close$4.14
52-week range$2.43 - $5.14
50-day moving average $4.06
200-day moving average $3.29
Wall St. target price$6.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.95

Buy Arbutus Biopharma Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arbutus Biopharma Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arbutus Biopharma Corporation price performance over time

Historical closes compared with the close of $4.14 from 2021-10-18

1 week (2021-10-09) N/A
1 month (2021-09-20) -3.50%
3 months (2021-07-20) 52.21%
6 months (2021-04-20) 38.46%
1 year (2020-10-20) 43.75%
2 years (2019-10-18) 346.51%
3 years (2018-10-19) 4.34
5 years (2016-10-20) 34.42%

Arbutus Biopharma Corporation financials

Revenue TTM $8.4 million
Gross profit TTM $-40,567,000
Return on assets TTM -34.75%
Return on equity TTM -86.05%
Profit margin 0%
Book value $1.03
Market capitalisation $404.6 million

TTM: trailing 12 months

Shorting Arbutus Biopharma Corporation shares

There are currently 2.8 million Arbutus Biopharma Corporation shares held short by investors – that's known as Arbutus Biopharma Corporation's "short interest". This figure is 24.8% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting Arbutus Biopharma Corporation shares can be evaluated.

Arbutus Biopharma Corporation's "short interest ratio" (SIR)

Arbutus Biopharma Corporation's "short interest ratio" (SIR) is the quantity of Arbutus Biopharma Corporation shares currently shorted divided by the average quantity of Arbutus Biopharma Corporation shares traded daily (recently around 3.5 million). Arbutus Biopharma Corporation's SIR currently stands at 0.8. In other words for every 100,000 Arbutus Biopharma Corporation shares traded daily on the market, roughly 800 shares are currently held short.

However Arbutus Biopharma Corporation's short interest can also be evaluated against the total number of Arbutus Biopharma Corporation shares, or, against the total number of tradable Arbutus Biopharma Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arbutus Biopharma Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Arbutus Biopharma Corporation shares in existence, roughly 30 shares are currently held short) or 0.0376% of the tradable shares (for every 100,000 tradable Arbutus Biopharma Corporation shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arbutus Biopharma Corporation.

Find out more about how you can short Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation share dividends

We're not expecting Arbutus Biopharma Corporation to pay a dividend over the next 12 months.

Have Arbutus Biopharma Corporation's shares ever split?

Arbutus Biopharma Corporation's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma Corporation shares which in turn could have impacted Arbutus Biopharma Corporation's share price.

Arbutus Biopharma Corporation share price volatility

Over the last 12 months, Arbutus Biopharma Corporation's shares have ranged in value from as little as $2.43 up to $5.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 2.682. This would suggest that Arbutus Biopharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arbutus Biopharma Corporation overview

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc. ; Alnylam Pharmaceuticals, Inc. ; Acuitas Therapeutics, Inc. ; and Antios Therapeutics, Inc.

Frequently asked questions

What percentage of Arbutus Biopharma Corporation is owned by insiders or institutions?
Currently 19.153% of Arbutus Biopharma Corporation shares are held by insiders and 29.796% by institutions.
How many people work for Arbutus Biopharma Corporation?
Latest data suggests 76 work at Arbutus Biopharma Corporation.
When does the fiscal year end for Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation's fiscal year ends in December.
Where is Arbutus Biopharma Corporation based?
Arbutus Biopharma Corporation's address is: 701 Veterans Circle, Warminster, PA, United States, 18974
What is Arbutus Biopharma Corporation's ISIN number?
Arbutus Biopharma Corporation's international securities identification number is: CA03879J1003
What is Arbutus Biopharma Corporation's CUSIP number?
Arbutus Biopharma Corporation's Committee on Uniform Securities Identification Procedures number is: 03879J100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site